Skip to main content

Table 4 Proteinuria incidence between third and twelve post-transplant months per MYH9 risk variant in additive, recessive and dominant models: Data for variables with P < 0.05 are shown in bold

From: Effect of donor non-muscle myosin heavy chain (MYH9) gene polymorphisms on clinically relevant kidney allograft dysfunction

  proteinuria month 3 proteinuria month 12 proteinuria between 3rd to 12th months
SNP genotype n Incidence (%) OR 95% CI P Incidence (%) OR 95% CI P Incidence (%) OR 95% CI P
rs11089788 AA 55 11.1     13.0     27.8   
AC 105 15.5 1.47 0.54–4.01 0.629ACvAA 13.5 1.04 0.39–2.76 1.000 ACvAA 26.0 0.91 0.43–1.92 0.850 ACvAA
CC 47 17.0 1.11 0.44–2.82 0.814 CCvAC 17.0 1.32 0.51–3.40 0.621 CCvAC 30.4 1.24 0.58–2.69 0.690 CCvAC
rs11089788 AA 55 11.1    13.0    27.8   
AC + CC 152 16.0 1.52 0.59–3.96 0.503 CvAA 14.6 1.14 0.46–2.85 1.000 CvAA 27.4 0.98 0.49–1.97 1.000 CvAA
rs11089788 CC 47 17.0    17.0    30.4   
AA+AC 160 14.0 1.26 0.52–3.05 0.609 CCvA 13.3 1.34 0.55–3.25 0.485 CCvA 26.6 1.21 0.58–2.48 0.707 CCvA
rs136211 AA 21 9.5    9.5    25.0   
AG 91 8.8 0.92 0.18–4.66 1.000 AGvAA 12.1 1.31 0.27–6.39 1.000 AGvAA 21.1 0.80 0.26–2.49 0.766 AGvAA
GG 95 21.7 2.88 1.206.94 0.023 GGvAG 17.2 1.51 0.66–3.46 0.406 GGvAG 34.4 1.96 1.01–3.83 0.067 GGvAG
rs136211 AA 21 9.5    9.5    25.0   
AG + GG 186 15.3 1.72 0.38–7.78 0.745 GvAA 14.7 1.63 0.36–7.42 0.745 GvAA 27.8 1.15 0.40–3.34 1.000 GvAA
rs136211 GG 95 21.7    17.2    21.8   
AG + AA 112 8.9 2.83 1.256.41 0.016 GGvA 11.6 1.58 0.72–3.49 0.315 GGvA 34.4 1.88 1.00–3.56 0.056 GGvA
rs3752462 CC 112 15.4    15.3    29.0   
CT 79 14.1 0.90 0.39–2.04 0.838 CTvCC 12.8 0.81 0.35–1.88 0.678 CTvCC 26.9 0.90 0.47–1.73 0.869 CTvCC
TT 16 12.5 0.87 0.17–4.37 1.000 TTvCT 12.5 0.97 0.19–4.92 1.000 TTvCT 20.0 0.68 0.17–2.64 0.752 TTvCT
rs3752462 CC 112 15.4    15.3    29.0   
CT + TT 95 13.8 0.88 0.40–1.92 0.844 TvCC 12.8 0.81 0.36–1.79 0.689 TvCC 25.8 0.85 0.46–1.59 0.637 TvCC
rs3752462 TT 16 12.5    12.5    20.0   
CC + CT 191 14.9 0.82 0.18–3.79 1.000TTvC 14.3 0.86 0.18–3.98 1.000 TTvC 28.1 0.64 0.17–2.36 0.764 TTvC
rs5756168 CC 3 33.3    33.3    33.3   
CT 39 5.1 0.11 0.01–1.76 0.204 CTvCC 7.7 0.17 0.01–2.42 0.265 CTvCC 18.4 0.45 0.04–5.71 0.488 CTvCC
TT 165 16.7 3.70 0.84–16.28 0.077 TTvCT 15.3 2.17 0.62–7.61 0.304 TTvCT 29.6 1.86 0.76–4.52 0.224 TTvCT
rs5756168 CC 3 33.3    33.3    33.3   
CT + TT 204 14.4 0.34 0.03–3.84 0.359 TvCC 13.9 0.32 0.03–3.67 0.369 TvCC 27.4 0.75 0.07–8.50 1.000 TvCC
rs5756168 TT 165 16.7    15.3    29.6   
CC + CT 42 7.1 2.60 0.75–9.03 0.147 TTvC 9.5 1.72 0.56–5.25 0.458 TTvC 19.5 1.73 0.74–4.03 0.241 TTvC
rs2239784 CC 187 15.2    15.1    28.7   
CT 20 10.0 0.62 0.14–2.82 0.744 CTvCC 5.0 0.29 0.04–2.29 0.320 CTvCC 15.8 0.46 0.13–1.66 0.289 CTvCC
TT 0          
rs2239784 CC 187 15.2       28.7   
CT + TT 20 10 0.62 0.14–2.82 0.744 TvCC    TvCC 15.8 0.46 0.13–1.66 0.289 TvCC
rs2239784 TT 0          
CC + CT 207 14.7         
rs4821480 GG 1 0    0    0   
GT 27 11.1   1.000 GTvGG 18.5   1.000 GTvGG 33.3   
TT 179 15.4 1.50 0.41–5.15 0.773 TTvGT 13.6 0.69 0.24–2.00 0.553 TTvGT 26.6 0.72 0.30–1.73 0.490 TTvGT
rs4821480 GG 1 0    0    0   
GT + TT 206 14.8    14.2    27.5   
rs4821480 TT 179 15.3    13.6    26.6   
GG + GT 28 10.7 1.51 0.43–5.35 0.774TTvG 17.8 0.72 0.25–2.08 0.561 TTvG 33.0 0.72 0.30–1.73 0.490 TTvG